| CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/46 (2025.01); A61P 31/14 (2018.01); C12N 5/0636 (2013.01)] | 3 Claims |
|
1. A method of treating adult T-cell leukemia, comprising administrating an injectable preparation to a patient in need thereof,
wherein the injectable preparation comprises a cell comprising one or more polynucleotides encoding a T cell receptor, the T-cell receptor comprising any one of the following features (A) to (J):
(A) a β chain comprising β chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, β chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, and β chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3, and an α chain comprising α chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 6, α chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 7, and α chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 8;
(B) a β chain comprising β chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 11, β chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 12, and β chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 13, and an α chain comprising α chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 16, α chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 17, and α chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 18;
(C) a β chain comprising β chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 21, β chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 22, and β chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 23, and an α chain comprising α chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:26, α chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 27, and α chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 28;
(D) a β chain comprising β chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 31, β chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 32, and β chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 33, and an α chain comprising α chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 36, α chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 37, and α chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 38;
(E) a β chain comprising β chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 41, β chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 42, and β chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 43, and an α chain comprising α chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 46, α chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 47, and α chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 48;
(F) a β chain comprising β chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 51, β chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 52, and β chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 53, and an α chain comprising α chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 56, α chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 57, and α chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 58;
(G) a β chain comprising β chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 61, β chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 62, and β chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 63, and an α chain comprising α chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 66, α chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 67, and α chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 68,
(H) a β chain comprising β chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 71, β chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 72, and β chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 73, and an α chain comprising α chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 76, α chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 77, and α chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 78,
(I) a β chain comprising β chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 81, β chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 82, and β chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 83, and an α chain comprising α chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 86, α chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 87, and α chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 88, and
(J) a β chain comprising β chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 91, β chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 92, and β chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 93, and an α chain comprising α chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 96, α chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 97, and α chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 98,
wherein the cell is a CD8-positive T cell, and
wherein the patient is HLA-A*24:02 or HLA-A*02:01 positive.
|